Global Antisense Oligonucleotides-based Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Antisense Oligonucleotides-based Therapeutics market size was valued at USD 3302.5 million in 2022 and is forecast to a readjusted size of USD 9669.6 million by 2029 with a CAGR of 16.6% during review period.
Antisense Oligonucleotides (ASOs) are a class of nucleic acid drugs designed to target specific RNA molecules within cells. They work by binding to complementary RNA sequences, which can modulate gene expression in various ways. ASOs have been developed to treat a wide range of genetic and other diseases.
The Antisense Oligonucleotide (ASO) Market is driven by the promising potential of ASOs in treating genetic disorders, rare diseases, and certain cancers by targeting specific RNA molecules and inhibiting their expression. ASOs represent a groundbreaking therapeutic approach that offers the possibility of highly targeted and personalized treatments. As our understanding of genomics and molecular biology advances, and precision medicine gains momentum, the demand for ASOs continues to grow. Innovations in ASO design, chemical modifications, and delivery technologies further contribute to market expansion. However, a significant challenge for this market is the need to address effective delivery to the target tissues, ensure long-term safety and efficacy, and navigate complex regulatory pathways. Overcoming delivery hurdles, minimizing off-target effects, and managing high development costs are ongoing challenges. Additionally, the market faces competition from traditional therapeutic approaches and the need for continuous research and development to fully unlock the therapeutic potential of ASOs. Striking a balance between providing safe, effective, and accessible ASO therapies while addressing scientific and regulatory challenges is essential for the continued growth of the Antisense Oligonucleotide (ASO) Market.
The Global Info Research report includes an overview of the development of the Antisense Oligonucleotides-based Therapeutics industry chain, the market status of Neuromuscular Diseases (With Chemical Modification, Without Chemical Modification), hATTR (With Chemical Modification, Without Chemical Modification), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Antisense Oligonucleotides-based Therapeutics.
Regionally, the report analyzes the Antisense Oligonucleotides-based Therapeutics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Antisense Oligonucleotides-based Therapeutics market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Antisense Oligonucleotides-based Therapeutics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Antisense Oligonucleotides-based Therapeutics industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., With Chemical Modification, Without Chemical Modification).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Antisense Oligonucleotides-based Therapeutics market.
Regional Analysis: The report involves examining the Antisense Oligonucleotides-based Therapeutics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Antisense Oligonucleotides-based Therapeutics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Antisense Oligonucleotides-based Therapeutics:
Company Analysis: Report covers individual Antisense Oligonucleotides-based Therapeutics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Antisense Oligonucleotides-based Therapeutics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Neuromuscular Diseases, hATTR).
Technology Analysis: Report covers specific technologies relevant to Antisense Oligonucleotides-based Therapeutics. It assesses the current state, advancements, and potential future developments in Antisense Oligonucleotides-based Therapeutics areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Antisense Oligonucleotides-based Therapeutics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Antisense Oligonucleotides-based Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chapter 1, to describe Antisense Oligonucleotides-based Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Antisense Oligonucleotides-based Therapeutics, with revenue, gross margin and global market share of Antisense Oligonucleotides-based Therapeutics from 2018 to 2023.
Chapter 3, the Antisense Oligonucleotides-based Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Antisense Oligonucleotides-based Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Antisense Oligonucleotides-based Therapeutics.
Chapter 13, to describe Antisense Oligonucleotides-based Therapeutics research findings and conclusion.
Antisense Oligonucleotides (ASOs) are a class of nucleic acid drugs designed to target specific RNA molecules within cells. They work by binding to complementary RNA sequences, which can modulate gene expression in various ways. ASOs have been developed to treat a wide range of genetic and other diseases.
The Antisense Oligonucleotide (ASO) Market is driven by the promising potential of ASOs in treating genetic disorders, rare diseases, and certain cancers by targeting specific RNA molecules and inhibiting their expression. ASOs represent a groundbreaking therapeutic approach that offers the possibility of highly targeted and personalized treatments. As our understanding of genomics and molecular biology advances, and precision medicine gains momentum, the demand for ASOs continues to grow. Innovations in ASO design, chemical modifications, and delivery technologies further contribute to market expansion. However, a significant challenge for this market is the need to address effective delivery to the target tissues, ensure long-term safety and efficacy, and navigate complex regulatory pathways. Overcoming delivery hurdles, minimizing off-target effects, and managing high development costs are ongoing challenges. Additionally, the market faces competition from traditional therapeutic approaches and the need for continuous research and development to fully unlock the therapeutic potential of ASOs. Striking a balance between providing safe, effective, and accessible ASO therapies while addressing scientific and regulatory challenges is essential for the continued growth of the Antisense Oligonucleotide (ASO) Market.
The Global Info Research report includes an overview of the development of the Antisense Oligonucleotides-based Therapeutics industry chain, the market status of Neuromuscular Diseases (With Chemical Modification, Without Chemical Modification), hATTR (With Chemical Modification, Without Chemical Modification), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Antisense Oligonucleotides-based Therapeutics.
Regionally, the report analyzes the Antisense Oligonucleotides-based Therapeutics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Antisense Oligonucleotides-based Therapeutics market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Antisense Oligonucleotides-based Therapeutics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Antisense Oligonucleotides-based Therapeutics industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., With Chemical Modification, Without Chemical Modification).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Antisense Oligonucleotides-based Therapeutics market.
Regional Analysis: The report involves examining the Antisense Oligonucleotides-based Therapeutics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Antisense Oligonucleotides-based Therapeutics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Antisense Oligonucleotides-based Therapeutics:
Company Analysis: Report covers individual Antisense Oligonucleotides-based Therapeutics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Antisense Oligonucleotides-based Therapeutics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Neuromuscular Diseases, hATTR).
Technology Analysis: Report covers specific technologies relevant to Antisense Oligonucleotides-based Therapeutics. It assesses the current state, advancements, and potential future developments in Antisense Oligonucleotides-based Therapeutics areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Antisense Oligonucleotides-based Therapeutics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Antisense Oligonucleotides-based Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- With Chemical Modification
- Without Chemical Modification
- Neuromuscular Diseases
- hATTR
- Other
- Sarepta Therapeutics
- Ionis Pharmaceuticals
- Biogen
- Nippon Shinyaku
- Sobi
- Jazz Pharmaceuticals
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Antisense Oligonucleotides-based Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Antisense Oligonucleotides-based Therapeutics, with revenue, gross margin and global market share of Antisense Oligonucleotides-based Therapeutics from 2018 to 2023.
Chapter 3, the Antisense Oligonucleotides-based Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Antisense Oligonucleotides-based Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Antisense Oligonucleotides-based Therapeutics.
Chapter 13, to describe Antisense Oligonucleotides-based Therapeutics research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Antisense Oligonucleotides-based Therapeutics
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Antisense Oligonucleotides-based Therapeutics by Type
1.3.1 Overview: Global Antisense Oligonucleotides-based Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Type in 2022
1.3.3 With Chemical Modification
1.3.4 Without Chemical Modification
1.4 Global Antisense Oligonucleotides-based Therapeutics Market by Application
1.4.1 Overview: Global Antisense Oligonucleotides-based Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Neuromuscular Diseases
1.4.3 hATTR
1.4.4 Other
1.5 Global Antisense Oligonucleotides-based Therapeutics Market Size & Forecast
1.6 Global Antisense Oligonucleotides-based Therapeutics Market Size and Forecast by Region
1.6.1 Global Antisense Oligonucleotides-based Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Antisense Oligonucleotides-based Therapeutics Market Size by Region, (2018-2029)
1.6.3 North America Antisense Oligonucleotides-based Therapeutics Market Size and Prospect (2018-2029)
1.6.4 Europe Antisense Oligonucleotides-based Therapeutics Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Antisense Oligonucleotides-based Therapeutics Market Size and Prospect (2018-2029)
1.6.6 South America Antisense Oligonucleotides-based Therapeutics Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Antisense Oligonucleotides-based Therapeutics Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Sarepta Therapeutics
2.1.1 Sarepta Therapeutics Details
2.1.2 Sarepta Therapeutics Major Business
2.1.3 Sarepta Therapeutics Antisense Oligonucleotides-based Therapeutics Product and Solutions
2.1.4 Sarepta Therapeutics Antisense Oligonucleotides-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sarepta Therapeutics Recent Developments and Future Plans
2.2 Ionis Pharmaceuticals
2.2.1 Ionis Pharmaceuticals Details
2.2.2 Ionis Pharmaceuticals Major Business
2.2.3 Ionis Pharmaceuticals Antisense Oligonucleotides-based Therapeutics Product and Solutions
2.2.4 Ionis Pharmaceuticals Antisense Oligonucleotides-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Ionis Pharmaceuticals Recent Developments and Future Plans
2.3 Biogen
2.3.1 Biogen Details
2.3.2 Biogen Major Business
2.3.3 Biogen Antisense Oligonucleotides-based Therapeutics Product and Solutions
2.3.4 Biogen Antisense Oligonucleotides-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Biogen Recent Developments and Future Plans
2.4 Nippon Shinyaku
2.4.1 Nippon Shinyaku Details
2.4.2 Nippon Shinyaku Major Business
2.4.3 Nippon Shinyaku Antisense Oligonucleotides-based Therapeutics Product and Solutions
2.4.4 Nippon Shinyaku Antisense Oligonucleotides-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Nippon Shinyaku Recent Developments and Future Plans
2.5 Sobi
2.5.1 Sobi Details
2.5.2 Sobi Major Business
2.5.3 Sobi Antisense Oligonucleotides-based Therapeutics Product and Solutions
2.5.4 Sobi Antisense Oligonucleotides-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Sobi Recent Developments and Future Plans
2.6 Jazz Pharmaceuticals
2.6.1 Jazz Pharmaceuticals Details
2.6.2 Jazz Pharmaceuticals Major Business
2.6.3 Jazz Pharmaceuticals Antisense Oligonucleotides-based Therapeutics Product and Solutions
2.6.4 Jazz Pharmaceuticals Antisense Oligonucleotides-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Jazz Pharmaceuticals Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Antisense Oligonucleotides-based Therapeutics Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Antisense Oligonucleotides-based Therapeutics by Company Revenue
3.2.2 Top 3 Antisense Oligonucleotides-based Therapeutics Players Market Share in 2022
3.2.3 Top 6 Antisense Oligonucleotides-based Therapeutics Players Market Share in 2022
3.3 Antisense Oligonucleotides-based Therapeutics Market: Overall Company Footprint Analysis
3.3.1 Antisense Oligonucleotides-based Therapeutics Market: Region Footprint
3.3.2 Antisense Oligonucleotides-based Therapeutics Market: Company Product Type Footprint
3.3.3 Antisense Oligonucleotides-based Therapeutics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Antisense Oligonucleotides-based Therapeutics Consumption Value and Market Share by Type (2018-2023)
4.2 Global Antisense Oligonucleotides-based Therapeutics Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Application (2018-2023)
5.2 Global Antisense Oligonucleotides-based Therapeutics Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2029)
6.2 North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2029)
6.3 North America Antisense Oligonucleotides-based Therapeutics Market Size by Country
6.3.1 North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2018-2029)
6.3.2 United States Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
6.3.3 Canada Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
6.3.4 Mexico Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2029)
7.2 Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2029)
7.3 Europe Antisense Oligonucleotides-based Therapeutics Market Size by Country
7.3.1 Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2018-2029)
7.3.2 Germany Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
7.3.3 France Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
7.3.5 Russia Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
7.3.6 Italy Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Antisense Oligonucleotides-based Therapeutics Market Size by Region
8.3.1 Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Region (2018-2029)
8.3.2 China Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
8.3.3 Japan Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
8.3.4 South Korea Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
8.3.5 India Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
8.3.7 Australia Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2029)
9.2 South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2029)
9.3 South America Antisense Oligonucleotides-based Therapeutics Market Size by Country
9.3.1 South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2018-2029)
9.3.2 Brazil Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
9.3.3 Argentina Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Antisense Oligonucleotides-based Therapeutics Market Size by Country
10.3.1 Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2018-2029)
10.3.2 Turkey Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
10.3.4 UAE Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Antisense Oligonucleotides-based Therapeutics Market Drivers
11.2 Antisense Oligonucleotides-based Therapeutics Market Restraints
11.3 Antisense Oligonucleotides-based Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Antisense Oligonucleotides-based Therapeutics Industry Chain
12.2 Antisense Oligonucleotides-based Therapeutics Upstream Analysis
12.3 Antisense Oligonucleotides-based Therapeutics Midstream Analysis
12.4 Antisense Oligonucleotides-based Therapeutics Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Antisense Oligonucleotides-based Therapeutics
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Antisense Oligonucleotides-based Therapeutics by Type
1.3.1 Overview: Global Antisense Oligonucleotides-based Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Type in 2022
1.3.3 With Chemical Modification
1.3.4 Without Chemical Modification
1.4 Global Antisense Oligonucleotides-based Therapeutics Market by Application
1.4.1 Overview: Global Antisense Oligonucleotides-based Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Neuromuscular Diseases
1.4.3 hATTR
1.4.4 Other
1.5 Global Antisense Oligonucleotides-based Therapeutics Market Size & Forecast
1.6 Global Antisense Oligonucleotides-based Therapeutics Market Size and Forecast by Region
1.6.1 Global Antisense Oligonucleotides-based Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Antisense Oligonucleotides-based Therapeutics Market Size by Region, (2018-2029)
1.6.3 North America Antisense Oligonucleotides-based Therapeutics Market Size and Prospect (2018-2029)
1.6.4 Europe Antisense Oligonucleotides-based Therapeutics Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Antisense Oligonucleotides-based Therapeutics Market Size and Prospect (2018-2029)
1.6.6 South America Antisense Oligonucleotides-based Therapeutics Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Antisense Oligonucleotides-based Therapeutics Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Sarepta Therapeutics
2.1.1 Sarepta Therapeutics Details
2.1.2 Sarepta Therapeutics Major Business
2.1.3 Sarepta Therapeutics Antisense Oligonucleotides-based Therapeutics Product and Solutions
2.1.4 Sarepta Therapeutics Antisense Oligonucleotides-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sarepta Therapeutics Recent Developments and Future Plans
2.2 Ionis Pharmaceuticals
2.2.1 Ionis Pharmaceuticals Details
2.2.2 Ionis Pharmaceuticals Major Business
2.2.3 Ionis Pharmaceuticals Antisense Oligonucleotides-based Therapeutics Product and Solutions
2.2.4 Ionis Pharmaceuticals Antisense Oligonucleotides-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Ionis Pharmaceuticals Recent Developments and Future Plans
2.3 Biogen
2.3.1 Biogen Details
2.3.2 Biogen Major Business
2.3.3 Biogen Antisense Oligonucleotides-based Therapeutics Product and Solutions
2.3.4 Biogen Antisense Oligonucleotides-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Biogen Recent Developments and Future Plans
2.4 Nippon Shinyaku
2.4.1 Nippon Shinyaku Details
2.4.2 Nippon Shinyaku Major Business
2.4.3 Nippon Shinyaku Antisense Oligonucleotides-based Therapeutics Product and Solutions
2.4.4 Nippon Shinyaku Antisense Oligonucleotides-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Nippon Shinyaku Recent Developments and Future Plans
2.5 Sobi
2.5.1 Sobi Details
2.5.2 Sobi Major Business
2.5.3 Sobi Antisense Oligonucleotides-based Therapeutics Product and Solutions
2.5.4 Sobi Antisense Oligonucleotides-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Sobi Recent Developments and Future Plans
2.6 Jazz Pharmaceuticals
2.6.1 Jazz Pharmaceuticals Details
2.6.2 Jazz Pharmaceuticals Major Business
2.6.3 Jazz Pharmaceuticals Antisense Oligonucleotides-based Therapeutics Product and Solutions
2.6.4 Jazz Pharmaceuticals Antisense Oligonucleotides-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Jazz Pharmaceuticals Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Antisense Oligonucleotides-based Therapeutics Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Antisense Oligonucleotides-based Therapeutics by Company Revenue
3.2.2 Top 3 Antisense Oligonucleotides-based Therapeutics Players Market Share in 2022
3.2.3 Top 6 Antisense Oligonucleotides-based Therapeutics Players Market Share in 2022
3.3 Antisense Oligonucleotides-based Therapeutics Market: Overall Company Footprint Analysis
3.3.1 Antisense Oligonucleotides-based Therapeutics Market: Region Footprint
3.3.2 Antisense Oligonucleotides-based Therapeutics Market: Company Product Type Footprint
3.3.3 Antisense Oligonucleotides-based Therapeutics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Antisense Oligonucleotides-based Therapeutics Consumption Value and Market Share by Type (2018-2023)
4.2 Global Antisense Oligonucleotides-based Therapeutics Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Application (2018-2023)
5.2 Global Antisense Oligonucleotides-based Therapeutics Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2029)
6.2 North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2029)
6.3 North America Antisense Oligonucleotides-based Therapeutics Market Size by Country
6.3.1 North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2018-2029)
6.3.2 United States Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
6.3.3 Canada Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
6.3.4 Mexico Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2029)
7.2 Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2029)
7.3 Europe Antisense Oligonucleotides-based Therapeutics Market Size by Country
7.3.1 Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2018-2029)
7.3.2 Germany Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
7.3.3 France Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
7.3.5 Russia Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
7.3.6 Italy Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Antisense Oligonucleotides-based Therapeutics Market Size by Region
8.3.1 Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Region (2018-2029)
8.3.2 China Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
8.3.3 Japan Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
8.3.4 South Korea Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
8.3.5 India Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
8.3.7 Australia Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2029)
9.2 South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2029)
9.3 South America Antisense Oligonucleotides-based Therapeutics Market Size by Country
9.3.1 South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2018-2029)
9.3.2 Brazil Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
9.3.3 Argentina Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Antisense Oligonucleotides-based Therapeutics Market Size by Country
10.3.1 Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2018-2029)
10.3.2 Turkey Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
10.3.4 UAE Antisense Oligonucleotides-based Therapeutics Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Antisense Oligonucleotides-based Therapeutics Market Drivers
11.2 Antisense Oligonucleotides-based Therapeutics Market Restraints
11.3 Antisense Oligonucleotides-based Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Antisense Oligonucleotides-based Therapeutics Industry Chain
12.2 Antisense Oligonucleotides-based Therapeutics Upstream Analysis
12.3 Antisense Oligonucleotides-based Therapeutics Midstream Analysis
12.4 Antisense Oligonucleotides-based Therapeutics Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Antisense Oligonucleotides-based Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Antisense Oligonucleotides-based Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Antisense Oligonucleotides-based Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Antisense Oligonucleotides-based Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Sarepta Therapeutics Company Information, Head Office, and Major Competitors
Table 6. Sarepta Therapeutics Major Business
Table 7. Sarepta Therapeutics Antisense Oligonucleotides-based Therapeutics Product and Solutions
Table 8. Sarepta Therapeutics Antisense Oligonucleotides-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Sarepta Therapeutics Recent Developments and Future Plans
Table 10. Ionis Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 11. Ionis Pharmaceuticals Major Business
Table 12. Ionis Pharmaceuticals Antisense Oligonucleotides-based Therapeutics Product and Solutions
Table 13. Ionis Pharmaceuticals Antisense Oligonucleotides-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Ionis Pharmaceuticals Recent Developments and Future Plans
Table 15. Biogen Company Information, Head Office, and Major Competitors
Table 16. Biogen Major Business
Table 17. Biogen Antisense Oligonucleotides-based Therapeutics Product and Solutions
Table 18. Biogen Antisense Oligonucleotides-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Biogen Recent Developments and Future Plans
Table 20. Nippon Shinyaku Company Information, Head Office, and Major Competitors
Table 21. Nippon Shinyaku Major Business
Table 22. Nippon Shinyaku Antisense Oligonucleotides-based Therapeutics Product and Solutions
Table 23. Nippon Shinyaku Antisense Oligonucleotides-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Nippon Shinyaku Recent Developments and Future Plans
Table 25. Sobi Company Information, Head Office, and Major Competitors
Table 26. Sobi Major Business
Table 27. Sobi Antisense Oligonucleotides-based Therapeutics Product and Solutions
Table 28. Sobi Antisense Oligonucleotides-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Sobi Recent Developments and Future Plans
Table 30. Jazz Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 31. Jazz Pharmaceuticals Major Business
Table 32. Jazz Pharmaceuticals Antisense Oligonucleotides-based Therapeutics Product and Solutions
Table 33. Jazz Pharmaceuticals Antisense Oligonucleotides-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Jazz Pharmaceuticals Recent Developments and Future Plans
Table 35. Global Antisense Oligonucleotides-based Therapeutics Revenue (USD Million) by Players (2018-2023)
Table 36. Global Antisense Oligonucleotides-based Therapeutics Revenue Share by Players (2018-2023)
Table 37. Breakdown of Antisense Oligonucleotides-based Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
Table 38. Market Position of Players in Antisense Oligonucleotides-based Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 39. Head Office of Key Antisense Oligonucleotides-based Therapeutics Players
Table 40. Antisense Oligonucleotides-based Therapeutics Market: Company Product Type Footprint
Table 41. Antisense Oligonucleotides-based Therapeutics Market: Company Product Application Footprint
Table 42. Antisense Oligonucleotides-based Therapeutics New Market Entrants and Barriers to Market Entry
Table 43. Antisense Oligonucleotides-based Therapeutics Mergers, Acquisition, Agreements, and Collaborations
Table 44. Global Antisense Oligonucleotides-based Therapeutics Consumption Value (USD Million) by Type (2018-2023)
Table 45. Global Antisense Oligonucleotides-based Therapeutics Consumption Value Share by Type (2018-2023)
Table 46. Global Antisense Oligonucleotides-based Therapeutics Consumption Value Forecast by Type (2024-2029)
Table 47. Global Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2023)
Table 48. Global Antisense Oligonucleotides-based Therapeutics Consumption Value Forecast by Application (2024-2029)
Table 49. North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 50. North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 51. North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 52. North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 53. North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 54. North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 55. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 56. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 57. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 58. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 59. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 60. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 61. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 62. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 63. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 64. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 65. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 66. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 67. South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 68. South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 69. South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 70. South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 71. South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 72. South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 73. Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 74. Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 75. Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 76. Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 77. Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 78. Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 79. Antisense Oligonucleotides-based Therapeutics Raw Material
Table 80. Key Suppliers of Antisense Oligonucleotides-based Therapeutics Raw Materials
LIST OF FIGURE
s
Figure 1. Antisense Oligonucleotides-based Therapeutics Picture
Figure 2. Global Antisense Oligonucleotides-based Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Type in 2022
Figure 4. With Chemical Modification
Figure 5. Without Chemical Modification
Figure 6. Global Antisense Oligonucleotides-based Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Application in 2022
Figure 8. Neuromuscular Diseases Picture
Figure 9. hATTR Picture
Figure 10. Other Picture
Figure 11. Global Antisense Oligonucleotides-based Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Antisense Oligonucleotides-based Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Market Antisense Oligonucleotides-based Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 14. Global Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 15. Global Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Region in 2022
Figure 16. North America Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 17. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 18. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 19. South America Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 20. Middle East and Africa Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 21. Global Antisense Oligonucleotides-based Therapeutics Revenue Share by Players in 2022
Figure 22. Antisense Oligonucleotides-based Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 23. Global Top 3 Players Antisense Oligonucleotides-based Therapeutics Market Share in 2022
Figure 24. Global Top 6 Players Antisense Oligonucleotides-based Therapeutics Market Share in 2022
Figure 25. Global Antisense Oligonucleotides-based Therapeutics Consumption Value Share by Type (2018-2023)
Figure 26. Global Antisense Oligonucleotides-based Therapeutics Market Share Forecast by Type (2024-2029)
Figure 27. Global Antisense Oligonucleotides-based Therapeutics Consumption Value Share by Application (2018-2023)
Figure 28. Global Antisense Oligonucleotides-based Therapeutics Market Share Forecast by Application (2024-2029)
Figure 29. North America Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 30. North America Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 31. North America Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 32. United States Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 33. Canada Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 34. Mexico Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 35. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 36. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 37. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 38. Germany Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 39. France Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 40. United Kingdom Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 41. Russia Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 42. Italy Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 43. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 44. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 45. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 46. China Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 47. Japan Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 48. South Korea Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 49. India Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 50. Southeast Asia Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 51. Australia Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 52. South America Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 53. South America Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 54. South America Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 55. Brazil Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 56. Argentina Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 57. Middle East and Africa Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 58. Middle East and Africa Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 59. Middle East and Africa Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 60. Turkey Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 61. Saudi Arabia Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 62. UAE Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 63. Antisense Oligonucleotides-based Therapeutics Market Drivers
Figure 64. Antisense Oligonucleotides-based Therapeutics Market Restraints
Figure 65. Antisense Oligonucleotides-based Therapeutics Market Trends
Figure 66. Porters Five Forces Analysis
Figure 67. Manufacturing Cost Structure Analysis of Antisense Oligonucleotides-based Therapeutics in 2022
Figure 68. Manufacturing Process Analysis of Antisense Oligonucleotides-based Therapeutics
Figure 69. Antisense Oligonucleotides-based Therapeutics Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
Table 1. Global Antisense Oligonucleotides-based Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Antisense Oligonucleotides-based Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Antisense Oligonucleotides-based Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Antisense Oligonucleotides-based Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Sarepta Therapeutics Company Information, Head Office, and Major Competitors
Table 6. Sarepta Therapeutics Major Business
Table 7. Sarepta Therapeutics Antisense Oligonucleotides-based Therapeutics Product and Solutions
Table 8. Sarepta Therapeutics Antisense Oligonucleotides-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Sarepta Therapeutics Recent Developments and Future Plans
Table 10. Ionis Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 11. Ionis Pharmaceuticals Major Business
Table 12. Ionis Pharmaceuticals Antisense Oligonucleotides-based Therapeutics Product and Solutions
Table 13. Ionis Pharmaceuticals Antisense Oligonucleotides-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Ionis Pharmaceuticals Recent Developments and Future Plans
Table 15. Biogen Company Information, Head Office, and Major Competitors
Table 16. Biogen Major Business
Table 17. Biogen Antisense Oligonucleotides-based Therapeutics Product and Solutions
Table 18. Biogen Antisense Oligonucleotides-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Biogen Recent Developments and Future Plans
Table 20. Nippon Shinyaku Company Information, Head Office, and Major Competitors
Table 21. Nippon Shinyaku Major Business
Table 22. Nippon Shinyaku Antisense Oligonucleotides-based Therapeutics Product and Solutions
Table 23. Nippon Shinyaku Antisense Oligonucleotides-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Nippon Shinyaku Recent Developments and Future Plans
Table 25. Sobi Company Information, Head Office, and Major Competitors
Table 26. Sobi Major Business
Table 27. Sobi Antisense Oligonucleotides-based Therapeutics Product and Solutions
Table 28. Sobi Antisense Oligonucleotides-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Sobi Recent Developments and Future Plans
Table 30. Jazz Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 31. Jazz Pharmaceuticals Major Business
Table 32. Jazz Pharmaceuticals Antisense Oligonucleotides-based Therapeutics Product and Solutions
Table 33. Jazz Pharmaceuticals Antisense Oligonucleotides-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Jazz Pharmaceuticals Recent Developments and Future Plans
Table 35. Global Antisense Oligonucleotides-based Therapeutics Revenue (USD Million) by Players (2018-2023)
Table 36. Global Antisense Oligonucleotides-based Therapeutics Revenue Share by Players (2018-2023)
Table 37. Breakdown of Antisense Oligonucleotides-based Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
Table 38. Market Position of Players in Antisense Oligonucleotides-based Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 39. Head Office of Key Antisense Oligonucleotides-based Therapeutics Players
Table 40. Antisense Oligonucleotides-based Therapeutics Market: Company Product Type Footprint
Table 41. Antisense Oligonucleotides-based Therapeutics Market: Company Product Application Footprint
Table 42. Antisense Oligonucleotides-based Therapeutics New Market Entrants and Barriers to Market Entry
Table 43. Antisense Oligonucleotides-based Therapeutics Mergers, Acquisition, Agreements, and Collaborations
Table 44. Global Antisense Oligonucleotides-based Therapeutics Consumption Value (USD Million) by Type (2018-2023)
Table 45. Global Antisense Oligonucleotides-based Therapeutics Consumption Value Share by Type (2018-2023)
Table 46. Global Antisense Oligonucleotides-based Therapeutics Consumption Value Forecast by Type (2024-2029)
Table 47. Global Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2023)
Table 48. Global Antisense Oligonucleotides-based Therapeutics Consumption Value Forecast by Application (2024-2029)
Table 49. North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 50. North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 51. North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 52. North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 53. North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 54. North America Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 55. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 56. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 57. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 58. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 59. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 60. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 61. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 62. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 63. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 64. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 65. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 66. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 67. South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 68. South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 69. South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 70. South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 71. South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 72. South America Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 73. Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 74. Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 75. Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 76. Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 77. Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 78. Middle East & Africa Antisense Oligonucleotides-based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 79. Antisense Oligonucleotides-based Therapeutics Raw Material
Table 80. Key Suppliers of Antisense Oligonucleotides-based Therapeutics Raw Materials
LIST OF FIGURE
s
Figure 1. Antisense Oligonucleotides-based Therapeutics Picture
Figure 2. Global Antisense Oligonucleotides-based Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Type in 2022
Figure 4. With Chemical Modification
Figure 5. Without Chemical Modification
Figure 6. Global Antisense Oligonucleotides-based Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Application in 2022
Figure 8. Neuromuscular Diseases Picture
Figure 9. hATTR Picture
Figure 10. Other Picture
Figure 11. Global Antisense Oligonucleotides-based Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Antisense Oligonucleotides-based Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Market Antisense Oligonucleotides-based Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 14. Global Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 15. Global Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Region in 2022
Figure 16. North America Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 17. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 18. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 19. South America Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 20. Middle East and Africa Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 21. Global Antisense Oligonucleotides-based Therapeutics Revenue Share by Players in 2022
Figure 22. Antisense Oligonucleotides-based Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 23. Global Top 3 Players Antisense Oligonucleotides-based Therapeutics Market Share in 2022
Figure 24. Global Top 6 Players Antisense Oligonucleotides-based Therapeutics Market Share in 2022
Figure 25. Global Antisense Oligonucleotides-based Therapeutics Consumption Value Share by Type (2018-2023)
Figure 26. Global Antisense Oligonucleotides-based Therapeutics Market Share Forecast by Type (2024-2029)
Figure 27. Global Antisense Oligonucleotides-based Therapeutics Consumption Value Share by Application (2018-2023)
Figure 28. Global Antisense Oligonucleotides-based Therapeutics Market Share Forecast by Application (2024-2029)
Figure 29. North America Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 30. North America Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 31. North America Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 32. United States Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 33. Canada Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 34. Mexico Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 35. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 36. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 37. Europe Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 38. Germany Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 39. France Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 40. United Kingdom Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 41. Russia Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 42. Italy Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 43. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 44. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 45. Asia-Pacific Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 46. China Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 47. Japan Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 48. South Korea Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 49. India Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 50. Southeast Asia Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 51. Australia Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 52. South America Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 53. South America Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 54. South America Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 55. Brazil Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 56. Argentina Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 57. Middle East and Africa Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 58. Middle East and Africa Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 59. Middle East and Africa Antisense Oligonucleotides-based Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 60. Turkey Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 61. Saudi Arabia Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 62. UAE Antisense Oligonucleotides-based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 63. Antisense Oligonucleotides-based Therapeutics Market Drivers
Figure 64. Antisense Oligonucleotides-based Therapeutics Market Restraints
Figure 65. Antisense Oligonucleotides-based Therapeutics Market Trends
Figure 66. Porters Five Forces Analysis
Figure 67. Manufacturing Cost Structure Analysis of Antisense Oligonucleotides-based Therapeutics in 2022
Figure 68. Manufacturing Process Analysis of Antisense Oligonucleotides-based Therapeutics
Figure 69. Antisense Oligonucleotides-based Therapeutics Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
